科济药业-B绩后涨超3% 中期净亏损7548.3万元 同比收窄78.53%

Core Viewpoint - 科济药业-B reported significant growth in its mid-year results for 2025, leading to a stock price increase of over 3% following the announcement [1] Financial Performance - Revenue reached 50.96 million, representing a year-on-year increase of 703.8% [1] - Gross profit amounted to 29.37 million, showing a substantial year-on-year growth of approximately 1,716% [1] - Net loss narrowed to 75.48 million, a reduction of 78.53% compared to the previous year [1] - Earnings per share reported a loss of 0.14 [1] Factors Influencing Performance - The reduction in losses was attributed to decreased research and development expenses, lower administrative costs, an increase in net foreign exchange gains, and higher gross profit [1]